Biomolecular Imaging: A Convoluted Promise
This article was originally published in Start Up
Executive Summary
Interest in biomolecular imaging--the ability to study metabolic pathways and changes at the molecular level using in vivo imaging--is intense, particularly as pharmaceutical and biotech companies look for ways to improve the efficiency of their drug development processes. But, as a recent NIH-sponsored forum shows, the field has a number of hurdles--regulatory, technical, and organizational--to address before it becomes part of mainstream medicine.
You may also be interested in...
Imaging in its Heyday: Clinical Applications (Part II)
As scientific innovation in molecular imaging explodes, experts believe the big payoff will be in clinical, rather than research, applications. But absent validating clinical data, businesses remain hesitant to jump into the field.
Imaging in its Heyday: Research Applications (Part 1)
Biomolecular imaging is upgrading diagnostic imaging's stodgy reputation as scientists increasingly use it to improve both pharmaceutical research and clinical care. Part I of a two-part series explores researchers' excitement about biomolecular imaging's potential to improve the drug development process. Many companies see research applications as a way to prime the marketplace for clinical applications. But venture capitalists think research is a limited opportunity.
GE Medical and Amersham Sharpen Their Molecular Image
With a surge in interest in molecular imaging, GE Medical Systems has been on the prowl for new technologies that improve performance of its PET and SPECT systems, so that clinicians can obtain information at the subcellular level. Amersham Health, too, has been been looking for better systems to help improve distribution and performance of its radiopharmaceutical labeling agents. Now the two are joining forces to create a next-generation compound for PET using new, easier-to-use chemistries.